rheumatologyadvisor3h
FDA Approves Denosumab Biosimilars Ospomyv and Xbryk
The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.
Managed Healthcare Executive3h
Lilly Lowers Prices of Some Zepbound Doses for Self-Pay Patients
Lowering the price of the 2.5 mg dose vial to $349 per month. Lowering the price of the 5 mg dose vial to $499 per month.